These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 8908943)
41. Advances in antiplatelet therapy for acute coronary syndromes. Clem JR; Falls S S D J Med; 1998 Jul; 51(7):233-4. PubMed ID: 9676157 [No Abstract] [Full Text] [Related]
42. Future trials of antiplatelet agents in cardiac ischemia. Throckmorton DC N Engl J Med; 2001 Jun; 344(25):1937-9. PubMed ID: 11419432 [No Abstract] [Full Text] [Related]
43. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? No. Ragosta M; Sarembock IJ J Thromb Haemost; 2004 Jan; 2(1):10-2. PubMed ID: 14717959 [No Abstract] [Full Text] [Related]
44. "IIb or not IIb or maybe IIb?" Is that the question? Or is it "which IIb and to whom?". Brinker JA Catheter Cardiovasc Interv; 2000 Oct; 51(2):145-6. PubMed ID: 11025565 [No Abstract] [Full Text] [Related]
45. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes. Exaire JE; Lincoff AM J Thromb Haemost; 2004 Jan; 2(1):7-9. PubMed ID: 14717958 [No Abstract] [Full Text] [Related]
46. Routine use of abciximab in coronary stenting? Stables RH Lancet; 1998 Jul; 352(9122):81-2. PubMed ID: 9672267 [No Abstract] [Full Text] [Related]
47. [Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomised trial]. Cavallini C Ital Heart J Suppl; 2001 Oct; 2(10):1124-6. PubMed ID: 11723618 [No Abstract] [Full Text] [Related]
48. Antiplatelet therapy for ischemic heart disease. Lange RA; Hillis LD N Engl J Med; 2004 Jan; 350(3):277-80. PubMed ID: 14724308 [No Abstract] [Full Text] [Related]
49. [Glycoprotein IIb/IIIa blockers. Their usefulness in current cardiovascular therapeutics]. López Cuéllar J Arch Inst Cardiol Mex; 1999; 69(3):272-81. PubMed ID: 10529862 [No Abstract] [Full Text] [Related]
50. [Should treatment with glycoprotein IIa/IIIb receptor blocker be controlled in patients undergoing coronary intervention?]. Heras M Rev Esp Cardiol; 2001 Nov; 54(11):1251-3. PubMed ID: 11707232 [No Abstract] [Full Text] [Related]
51. Glycoprotein inhibitors and fibrinolysis in myocardial infarction. Ring BL JAMA; 2000 Dec; 284(24):3124-5. PubMed ID: 11135766 [No Abstract] [Full Text] [Related]
52. [Monoclonal antibodies in cardiology]. Legrand V Rev Med Liege; 2009; 64(5-6):310-2. PubMed ID: 19642465 [TBL] [Abstract][Full Text] [Related]
53. Massive pulmonary hemorrhage in a patient treated with a platelet glycoprotein IIb/IIIa inhibitor. Sitges M; Villa FP Int J Cardiol; 1997 Dec; 62(3):269-71. PubMed ID: 9476687 [TBL] [Abstract][Full Text] [Related]
54. Avoidance of adverse events in restenotic lesions with abciximab? Linnemeier TJ J Invasive Cardiol; 2000 Nov; 12(11):545-6. PubMed ID: 11060564 [No Abstract] [Full Text] [Related]
58. Dosing and administration of ReoPro (c7E3 Fab). Tcheng JE J Invasive Cardiol; 1994; 6 Suppl A():29A-33A; discussion 51A-54A. PubMed ID: 10155091 [No Abstract] [Full Text] [Related]
59. Inflammation as a therapeutic target: a unique role for abciximab. Kereiakes DJ Am Heart J; 2003 Oct; 146(4 Suppl):S1-4. PubMed ID: 14564299 [TBL] [Abstract][Full Text] [Related]
60. Mechanical reperfusion: treat well, treat on time too. Montalescot G Lancet; 2008 Aug; 372(9638):509-10. PubMed ID: 18707968 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]